ClinicalTrials.gg
CompletedNCT06582602Updated May 21, 2025

A Study of MK-2060 in Healthy Participants (MK-2060-016)

A Phase 1 interventional study of MK-2060 and Placebo in Venous Thrombosis, sponsored by Merck Sharp & Dohme LLC. Completed at 2 sites in United States. Open to participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-05-21.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Apr 2025, 1 year 6 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
23
Allocation
Randomized
Ages
18 Years to 50 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 246 studies in Venous Thrombosis with a site in United States — 23 open to participants now, 31 under way, 5 of them phase 3. Venous Thrombosis · United States.

Enrollment
152nd of 184
23 · median 130
Started
2024
with 4 others
Phase 1
15 of 246
1 open now
Registered
228th of 246
by date

Among the 246 studies in Venous Thrombosis with a site in United States, this one is the 152nd largest by enrollment of the 184 interventional ones that give a count, is one of 5 that started in 2024, is one of 15 in phase 1, and was the 228th registered.

Venous Thrombosis

785 studies on the registry are indexed under Venous Thrombosis; 110 are open to participants now.

Browse Venous Thrombosis studies →

Open to participants now

23 of the 246 studies in Venous Thrombosis with a site in United States are open now. Recruiting first, the newest first:

18 more — sign in →

All 23 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 84 Venous Thrombosis studies recruiting now, 59 (70%) set no upper age limit and 9 (11%) stop at 75 or younger; 10 take children under 18; 7 take healthy volunteers.

This study: 18 Years to 50 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 246 studies in Venous Thrombosis with a site in United States, or all of them as a file.
02

Study summary

The goal of the study is to learn about the safety of MK-2060 and if people tolerate it when MK-2060 is given in different forms.

03

Conditions studied

  • Venous Thrombosis

Browse trials for

04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

The key inclusion criteria include but are not limited to the following:

  • Is in good health before randomization
  • Has a (BMI) between ≥18 and ≤32 kg/m\^2, inclusive

Exclusion criteria

Exclusion Criteria:

The key exclusion criteria include but are not limited to the following:

  • Has a history of endocrine, gastrointestinal (GI), cardiovascular, hematological, hepatic, immunological, renal, respiratory, genitourinary, or major neurological (including stroke and chronic seizures) abnormalities or diseases
  • Has a history of cancer
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
23 participants (actual)

Study arms

  • Experimental
    Panel A: MK-2060 IV (20 minutes)

    Participants will receive a single dose of MK-2060 via intravenous (IV) infusion over 20 minutes on Day 1.

    Biological: MK-2060

  • Experimental
    Panel B: MK-2060 IV (10 minutes)

    Participants will receive a single dose of MK-2060 via IV infusion over 10 minutes on Day 1.

    Biological: MK-2060

  • Experimental
    Panel C: MK-2060 IV (5 minutes)

    Participants will receive a single dose of MK-2060 via syringe over 5 minutes on Day 1.

    Biological: MK-2060

  • Experimental
    Panel D: MK-2060 IV (2.5 minutes)

    Participants will receive a single dose of MK-2060 via syringe over 2.5 minutes on Day 1.

    Biological: MK-2060

  • Experimental
    Panel E: MK-2060 IV (1 minute)

    Participants will receive a single dose of MK-2060 via syringe over 1 minute on Day 1.

    Biological: MK-2060

  • Placebo comparator
    Placebo

    Participants will receive a single dose of saline via IV infusion or syringe over MK-2060-matched time period on Day 1.

    Biological: Placebo

Interventions

  • BiologicalMK-2060

    Single doses of MK-2060 will be administered via IV infusion or syringe on Day 1 according to randomization.

  • BiologicalPlacebo

    Single doses of placebo will be administered via IV infusion or syringe on Day 1 according to randomization.

06

What researchers measure

Primary outcomes

  1. Number of Participants With An Adverse Event (AE)

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. The number of participants that experience an AE will be reported.

    Time frame: Up to 134 days

  2. Number of Participants Discontinuing the Study Due to an AE

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. The number of participants that discontinue the study due to an AE will be reported.

    Time frame: Up to 134 days

Secondary outcomes

  1. Area Under the Plasma Concentration-Time Curve of MK-2060 From Time 0 to Infinity (AUC0-inf)

    Plasma samples will be collected at pre-specified time points pre- and post-dose to assess AUC0-inf.

    Time frame: Predose and at designated time points post dose up to 120 days

  2. Maximum Observed Plasma Concentration (Cmax) of MK-2060

    Plasma samples will be collected at pre-specified time points pre- and post-dose to assess Cmax.

    Time frame: Predose and at designated time points post dose up to 120 days

  3. Area Under the Plasma Concentration-Time Curve of MK-2060 From Time 0 to 168 Hours (AUC0-168)

    Plasma samples will be collected at pre-specified time points pre- and post-dose to assess AUC0-168 hours.

    Time frame: Predose and at designated time points post dose up to 120 days

  4. Plasma Concentration of MK-2060 at 168 Hours (C168)

    Plasma samples will be collected at pre-specified time points pre- and post-dose to assess C168 hours.

    Time frame: Predose and at designated time points post dose up to 120 days

  5. Time to Maximum Observed Plasma Drug Concentration (Tmax) of MK-2060

    Plasma samples will be collected at pre-specified time points pre- and post-dose to assess Tmax.

    Time frame: Predose and at designated time points post dose up to 120 days

  6. Plasma Elimination Terminal Half-life (t ½) of MK-2060

    Plasma samples will be collected at pre-specified time points pre- and post-dose to assess t½ .

    Time frame: Predose and at designated time points post dose up to 120 days

  7. Apparent Oral Clearance (CL/F) of MK-2060

    Plasma samples will be collected at pre-specified time points pre- and post-dose to assess CL/F.

    Time frame: Predose and at designated time points post dose up to 120 days

  8. Plasma Apparent Volume of Distribution (Vz/F) of MK-2060

    Plasma samples will be collected at pre-specified time points pre- and post-dose to assess Vz/F.

    Time frame: Predose and at designated time points post dose up to 120 days

  9. Fold Change From Baseline in Activated Partial Thromboplastin Time (aPTT) of MK-2060

    Plasma samples will be collected at baseline and pre-specified time points post-dose to assess aPTT values. The fold change from baseline will be reported.

    Time frame: Baseline and up to 120 days

07

Study locations

2 sites
  • Advanced Pharma CR, LLC ( Site 0002)
    Miami, Florida 33147, United States
  • Alliance for Multispecialty Research, LLC ( Site 0001)
    Knoxville, Tennessee 37920, United States
08

References and documents

Individual participant data

Plan to share: Yes — https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf

Data sharing details ↗ · externaldatasharing-msd.com

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2024 to primary completion in Apr 2025, 6 months.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 30, 2024
First posted
Sep 3, 2024
StartActual
Oct 15, 2024
Primary completionActual
Apr 18, 2025
CompletionActual
Apr 18, 2025
Last update
May 21, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 21, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06582602
Responsible party
Sponsor
First posted
Sep 3, 2024
Start date
Oct 15, 2024
Primary completion
Apr 18, 2025
Completion
Apr 18, 2025
Last update
May 21, 2025

Study contacts

Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: MK-2060

Start the discussion